Hungary's Richter and Hikma receive FDA approval for denosumab biosimilars
View all comments(0)
BUDAPEST, Sept 29 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU says in a statement:
RICHTER AND HIKMA RECEIVE FDA APPROVAL FOR DENOSUMAB BIOSIMILARS ENOBYTM AND XTRENBO, REFERENCING PROLIA AND XGEVA, RESPECTIVELY
UNDER THE TERMS OF THE AGREEMENT RICHTER IS RESPONSIBLE FOR THE DEVELOPMENT AND MANUFACTURE OF THE PRODUCTS
HIKMA IS RESPONSIBLE FOR THE FDA REGISTRATION AND EXCLUSIVE COMMERCIALIZATION IN THE U.S.
DENOSUMAB IS INDICATED FOR TREATING OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
Source text: [https://www.bse.hu/newkibdata/129324268/Denosumab_FDA_Approval_Sep2025_EN.pdf]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey








Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.